艾迪药业2024亏损连亏4年 2020年上市募资8.4亿元

Core Points - The company reported a revenue of 419.265 million yuan for the 2024 fiscal year, representing a year-on-year increase of 1.92% [1] - The net profit attributable to the parent company was -129.9185 million yuan, a decrease of 70.79% compared to the previous year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -147.8274 million yuan, down 67.87% year-on-year [1] Financial Performance - The company's net profits for the years 2021, 2022, and 2023 were -29.9856 million yuan, -124 million yuan, and -76.0695 million yuan respectively [2] - The company plans to raise up to 100 million yuan through a private placement of A-shares, with the net proceeds intended for working capital [2] Stock Information - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 20, 2020, with an initial offering of 60 million shares at a price of 13.99 yuan per share [1] - The stock is currently in a state of decline, having fallen below its initial offering price [1] Fundraising and Use of Proceeds - The total amount raised during the initial public offering was 839.4 million yuan, with a net amount of 764.07 million yuan after expenses [1] - The company intends to use the funds raised for innovative drug research and development, purchasing a research and development center building, and repaying bank loans [1]